| 1 | ITCH, TAZ, YAP1, YOD1
|
| Deubiquitinase YOD1: The Potent Activator of YAP in Hepatomegaly and Liver Cancer.
|
| Kim Y, Jho EH.
|
| BMB Rep MB Rep. 2017 May 15. pii: 3845. [Epub ahead of print]
2017
|
| 2 | ITCH, TAZ, YAP1, YOD1
|
| Deubiquitinase YOD1 potentiates YAP/TAZ activities through enhancing ITCH stability.
|
| Kim Y, Kim W, Song Y, Kim JR, Cho K, Moon H, Ro SW, Seo E, Ryu YM, Myung SJ, Jho EH.
|
| Proc Natl Acad Sci U S A 114(18):4691-4696. doi: 10.1073/pnas.1620306114. Epub 2017 Apr 17.
2017
|
| 3 | TRAF6, YOD1
|
| YOD1/TRAF6 association balances p62-dependent IL-1 signaling to NF-κB.
|
| Schimmack G, Schorpp K, Kutzner K, Gehring T, Brenke JK, Hadian K, Krappmann D.
|
| Elife 6. pii: e22416. doi: 10.7554/eLife.22416.
2017
|
| 4 | PLAA, UBXN6, VCP, YOD1
|
| VCP/p97 cooperates with YOD1, UBXD1 and PLAA to drive clearance of ruptured lysosomes by autophagy.
|
| Papadopoulos C, Kirchner P, Bug M, Grum D, Koerver L, Schulze N, Poehler R, Dressler A, Fengler S, Arhzaouy K, Lux V, Ehrmann M, Weihl CC, Meyer H.
|
| EMBO J 36(2):135-150. doi: 10.15252/embj.201695148. Epub 2016 Oct 17.
2017
|
| 5 | VCP, YOD1
|
| The VCP/p97 and YOD1 Proteins Have Different Substrate-dependent Activities in Endoplasmic Reticulum-associated Degradation (ERAD).
|
| Sasset L, Petris G, Cesaratto F, Burrone OR.
|
| J Biol Chem 290(47):28175-88. doi: 10.1074/jbc.M115.656660. Epub 2015 Oct 13.
2015
|
| 6 | YOD1
|
| A catalytically inactive mutant of the deubiquitylase YOD-1 enhances antigen cross-presentation.
|
| Sehrawat S, Koenig PA, Kirak O, Schlieker C, Fankhauser M, Ploegh HL.
|
| Blood 121(7):1145-56. doi: 10.1182/blood-2012-08-447409. Epub 2012 Dec 13.
2013
|
| 7 | VCP, YOD1
|
| The otubain YOD1 is a deubiquitinating enzyme that associates with p97 to facilitate protein dislocation from the ER.
|
| Ernst R, Mueller B, Ploegh HL, Schlieker C.
|
| Mol Cell 36(1):28-38. doi: 10.1016/j.molcel.2009.09.016.
2009
|